Deep penetrating nevus-like borderline tumors: A unique subset of ambiguous melanocytic tumors with malignant potential and normal cytogenetics.

TitleDeep penetrating nevus-like borderline tumors: A unique subset of ambiguous melanocytic tumors with malignant potential and normal cytogenetics.
Publication TypeJournal Article
Year of Publication2014
AuthorsMagro CM, Abraham RM, Guo R, Li S, Wang X, Proper S, A Crowson N, Mihm M
JournalEur J Dermatol
Volume24
Issue5
Pagination594-602
Date Published2014 Sep-Oct
ISSN1952-4013
KeywordsAdolescent, Adult, Cell Transformation, Neoplastic, Child, Chromosomes, Human, Pair 11, Chromosomes, Human, Pair 6, Comparative Genomic Hybridization, Cyclin D1, Disease Progression, DNA-Binding Proteins, Female, Genes, myb, Humans, In Situ Hybridization, Fluorescence, Lymphatic Metastasis, Male, Melanoma, Middle Aged, Nevus, Pigmented, Sentinel Lymph Node Biopsy, Skin Neoplasms, Transcription Factors, Young Adult
Abstract

BACKGROUND: Deep penetrating nevi (DPN) are a relatively uncommon subtype of melanocytic nevi. A small subset of these lesions exhibit atypical features (cytologic and architectural atypia, mitotic activity) seen in melanoma. These lesions we term the deep penetrating nevus-like borderline tumor. Unequivocal melanomas can show overlapping morphologic features of DPN, which have been termed plexiform melanomas.

PATIENTS AND METHODS: 40 cases of DPN-like borderline tumor were identified along with 6 cases of plexiform melanoma. Clinical follow up was obtained, along with cytogenetic analysis in the form of fluorescent in situ hybridization (FISH) and/or comparative genomic hybridization (CGH).

RESULTS: The DPN-like borderline tumor cases included 24 females and 16 males. Of sentinel lymph node biopsies performed, 1/3 of cases showed lymph node involvement. All patients where an aggressive clinical approach was adopted remain free of disease. All 6 DPN-like borderline tumor cases tested by CGH showed normal cytogenetics, as did 7 of 9 cases tested by FISH. Of the plexiform melanomas, 4/6 patients died of disease. In 3 cases there was morphologic progression from a DPN-like borderline tumor to overt melanoma. In one case of progression, cytogenetics was normal in the DPN-like borderline tumor and then abnormal in the progressed melanoma.

CONCLUSION: DPN-like borderline tumors are melanocytic tumors associated with a high incidence of regional lymph node disease and exhibiting the potential for melanoma progression despite a normal cytogenetic profile. Patients with these lesions should be aggressively managed, with at least complete re-excision and consideration of sentinel node biopsy, regardless of cytogenetic data.

DOI10.1684/ejd.2014.2393
Alternate JournalEur J Dermatol
PubMed ID25118781
Related Faculty: 
Cynthia M. Magro, M.D. Xuan Wang, M.D., Ph.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700